

Simone Lista

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/863454/publications.pdf>

Version: 2024-02-01

144
papers

7,878
citations

87401

40
h-index

64407

83
g-index

153
all docs

153
docs citations

153
times ranked

10716
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
2	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	4.9	434
3	The β -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 745-756.	0.7	336
4	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.4	232
5	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.4	227
6	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
7	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.4	205
8	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	2.2	201
9	Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346.	4.9	161
10	Exercise benefits on Alzheimer's disease: State-of-the-science. <i>Ageing Research Reviews</i> , 2020, 62, 101108.	5.0	153
11	Relevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 399-424.	1.1	151
12	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. <i>Brain</i> , 2019, 142, 2096-2112.	3.7	131
13	Revolution of Alzheimer Precision Neurology. <i>Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease</i> , 2018, 64, S47-S105.	1.2	122
14	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.4	122
15	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2013, 101-102, 1-17.	2.8	115
16	Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. <i>Alzheimer's and Dementia</i> , 2012, 8, 312-336.	0.4	112
17	A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. <i>Climacteric</i> , 2017, 20, 107-118.	1.1	112
18	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 59-71.	0.4	112

#	ARTICLE	IF	CITATIONS
19	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449.	2.0	105
20	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315.	0.4	104
21	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1041-1049.	0.4	102
22	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β ₁₋₄₂ , total tau, phosphorylated tau, NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501.	0.4	91
23	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018, 83, 447-455.	0.7	83
24	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 11706.	1.6	79
25	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
26	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018, 14, 1204-1215.	0.4	79
27	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017, 14, 285-299.	1.3	78
28	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 291-317.	1.2	75
29	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1-24.	1.2	75
30	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021, 69, 101346.	5.0	74
31	Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 47-57.	1.4	65
32	CSF A β ₁₋₄₂ combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392.		64
33	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
34	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.4	58
35	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <i>Frontiers in Neuroscience</i> , 2020, 14, 585432.	1.4	57
36	Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2011, 32, 1231-1235.	1.5	56

#	ARTICLE	IF	CITATIONS
37	Paths to Alzheimer's disease prevention: From modifiable risk factors to biomarker enrichment strategies. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 154-163.	1.5	50
38	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	1.5	48
39	Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. <i>Ageing Research Reviews</i> , 2021, 72, 101479.	5.0	48
40	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	1.9	46
41	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , 2018, 50, 31-51.	2.5	46
42	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. <i>Annals of Nuclear Medicine</i> , 2018, 32, 75-86.	1.2	45
43	Association of cerebrospinal fluid τ_{181} protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631.	0.4	45
44	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 27-34.	1.2	44
45	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 615-629.	1.2	44
46	Biological and methodical challenges of blood-based proteomics in the field of neurological research. <i>Progress in Neurobiology</i> , 2013, 101-102, 18-34.	2.8	43
47	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 940-950.	0.4	43
48	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	1.5	42
49	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019, 16, 593-600.	1.3	41
50	The rising global tide of cognitive impairment. <i>Nature Reviews Neurology</i> , 2016, 12, 131-132.	4.9	40
51	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.4	39
52	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , 2019, 181, 101662.	2.8	38
53	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1631-e1638.	1.1	38
54	From inherited to sporadic AD "crossing the biomarker bridge. <i>Nature Reviews Neurology</i> , 2012, 8, 598-600.	4.9	36

#	ARTICLE	IF	CITATIONS
55	Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. <i>Methods in Molecular Biology</i> , 2018, 1750, 31-66.	0.4	36
56	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	1.2	35
57	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , 2019, 10, 310.	1.6	35
58	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	1.2	34
59	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. <i>Trends in Neurosciences</i> , 2017, 40, 469-480.	4.2	34
60	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	1.9	33
61	Imaging Epigenetics in Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 6393-6415.	0.9	33
62	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. <i>Frontiers in Neurology</i> , 2018, 9, 642.	1.1	32
63	Disrupted white matter structural networks in healthy older adult APOE ϵ 4 carriers – An international multicenter DTI study. <i>Neuroscience</i> , 2017, 357, 119-133.	1.1	31
64	Successful aging: insights from proteome analyses of healthy centenarians. <i>Aging</i> , 2020, 12, 3502-3515.	1.4	31
65	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <i>Journal of Neurology</i> , 2014, 261, 1234-1243.	1.8	30
66	Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2016, 1303, 49-67.	0.4	30
67	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- β 2 Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019, 290, 167-176.	3.6	30
68	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020, 90, 43-59.	1.5	30
69	Physical Exercise and Alzheimer's Disease: Effects on Pathophysiological Molecular Pathways of the Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2897.	1.8	30
70	Defining and assessing intrinsic capacity in older people: A systematic review and a proposed scoring system. <i>Ageing Research Reviews</i> , 2022, 79, 101640.	5.0	30
71	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 67.	1.7	29
72	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 54-63.	1.5	28

#	ARTICLE	IF	CITATIONS
73	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 793-804.	1.2	28
74	The phenotypical core of Alzheimer's disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. <i>Alzheimer's and Dementia</i> , 2016, 12, 786-795.	0.4	28
75	Optimization protocol for amyloid β peptides detection in human cerebrospinal fluid using SELDI TOF MS. <i>Proteomics - Clinical Applications</i> , 2010, 4, 352-357.	0.8	27
76	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	2.0	27
77	Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. <i>Learning and Memory</i> , 2010, 17, 236-240.	0.5	26
78	Increased Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 877-886.	1.2	26
79	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 87-106.	1.8	26
80	Brain β load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019, 15, 1274-1285.	0.4	25
81	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 5-18.	1.8	23
82	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , 2016, 108, 128-135.	2.0	23
83	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	3.0	23
84	Coronavirus Lockdown: Forced Inactivity for the Oldest Old?. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 988-989.	1.2	23
85	Biomarker-guided classification scheme of neurodegenerative diseases. <i>Journal of Sport and Health Science</i> , 2016, 5, 383-387.	3.3	22
86	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 93, 98-108.	1.5	21
87	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study. <i>Alzheimer's and Dementia</i> , 2018, 14, 1126-1136.	0.4	20
88	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41.	1.5	20
89	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2017, 19, 154-160.	1.8	18
90	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 129.	3.0	18

#	ARTICLE	IF	CITATIONS
91	Association of plasma YKL-40 with brain amyloid- β^2 levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	1.5	18
92	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. <i>Neurobiology of Aging</i> , 2017, 57, 143-152.	1.5	18
93	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 177-191.	1.8	17
94	β -Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	3.0	16
95	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <i>Journal of Personalized Medicine</i> , 2020, 10, 138.	1.1	15
96	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115.	0.4	14
97	Role of amyloid β^{1-42} and neuroimaging biomarkers in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2011, 5, 411-413.	0.6	13
98	MiRNA-15b and miRNA-125b are associated with regional $A\beta$ -PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021, 11, 78.	2.4	13
99	A frontline defense against neurodegenerative diseases:the development of early disease detection methods. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 559-563.	1.5	12
100	The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 57.	3.0	12
101	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018, 1750, 139-155.	0.4	12
102	Blood-based diagnostics of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 613-621.	1.5	11
103	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 84-90.	0.9	10
104	Plasma β -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640.	0.4	10
105	Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. <i>PLoS ONE</i> , 2018, 13, e0190212.	1.1	8
106	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 553-562.	1.8	8
107	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 151-164.	1.2	7
108	Exercise and the hallmarks of peripheral arterial disease. <i>Atherosclerosis</i> , 2022, 350, 41-50.	0.4	6

#	ARTICLE	IF	CITATIONS
109	TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER'S DISEASE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-5.	1.5	5
110	Aptamer prediction of brain amyloid- β status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021, 16, e0243902.	1.1	5
111	Association of plasma A β ₄₀ /A β ₄₂ ratio and brain A β accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 107, 57-69.	1.5	5
112	Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 11.	3.0	4
113	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 88, 83-90.	1.5	4
114	COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER'S DISEASE LIQUID BIOPSY. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-3.	1.5	3
115	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748198.	1.7	3
116	Potential therapeutical effects of topical halofuginone hydrobromide in keloid management. <i>Medical Hypotheses</i> , 2007, 69, 707.	0.8	2
117	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 577-583.	1.2	2
118	Aging and sex impact plasma NFL and τ trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041792.	0.4	2
119	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P541-P542.		1
120	[P2-379]: ACCURACY OF MRI CLASSIFICATION ALGORITHMS IN A TERTIARY MEMORY CENTER CLINICAL ROUTINE COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P772.	0.4	1
121	P3-218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: A β ₁₋₄₂ , TOTAL τ , PHOSPHORYLATED τ , NFL, NEUROGRANIN, AND YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, P1154.	0.4	1
122	P1-431: APOE-DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P474.	0.4	1
123	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. <i>Current Neuropharmacology</i> , 2021, 19, .	1.4	1
124	An expanded microarray platform for diagnosis of nonbacterial sepsis: Potential usefulness for immunosuppressed patients. <i>Medical Hypotheses</i> , 2006, 67, 1001.	0.8	0
125	Analysis of mitochondrial DNA by PCR/DHPLC as a diagnostic tool to differentiate schistosomes species and strains. <i>Medical Hypotheses</i> , 2007, 68, 707-708.	0.8	0
126	Demineralized bone matrix enriched with human recombinant interleukin-11: A novel therapeutic option in treatment of delayed unions and nonunions?. <i>Medical Hypotheses</i> , 2007, 69, 954.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. Medical Hypotheses, 2008, 71, 162.	0.8	0
128	Schizophrenia: Blood-Serum-Plasma Metabolomics. Advances in Biological Psychiatry, 2014, , 27-27.	0.2	0
129	IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P37-P37.		0
130	P4â€072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. Alzheimer's and Dementia, 2018, 14, P1461.	0.4	0
131	P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762.	0.4	0
132	O4â€07â€04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. Alzheimer's and Dementia, 2018, 14, P1419.	0.4	0
133	O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036.	0.4	0
134	P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510.	0.4	0
135	P2â€397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN. Alzheimer's and Dementia, 2018, 14, P855.	0.4	0
136	P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767.	0.4	0
137	P2â€249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P768.	0.4	0
138	O3â€12â€04: THE NEURONAL COMPENSATION MODEL OF THE PRECLINICAL STAGE OF ALZHEIMER'S DISEASE: RESULTS FROM THE INSIGHTâ€PRE AD STUDY. Alzheimer's and Dementia, 2018, 14, P1051.	0.4	0
139	P2â€355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P824.	0.4	0
140	Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753.	0.4	0
141	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. Alzheimer's and Dementia, 2020, 16, e045832.	0.4	0
142	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e046014.	0.4	0
143	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046105.	0.4	0
144	Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEGâ€fMRI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0